30日間連続 1ch 心電図ホルター又は二週間連続モニター用設定可 FDA認可済 本邦研究用

30日間連続 1ch 心電図ホルター又は二週間連続モニター用設定可 FDA認可済 本邦研究用

体温センサー 0.1°精度 72時間 ディスポ スマホ・タブレット連携 FDA認可 本邦研究用

体温センサー 0.1°精度 72時間 ディスポ スマホ・タブレット連携 FDA認可 本邦研究用

2009年11月8日日曜日

血管造影剤は腎臓疾患に影響、特に糖尿病疾患には

Clin Res Cardiol Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI
Ingo Wickenbrock . Christian Perings . Petra Maagh . Received: 24 March 2009 / Accepted: 30 July 2009 Abstract The aim of this study was to assess the incidence, clinical predictors, and outcome of patients developing contrast medium induced nephropathy (CIN) after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Background CIN is associated with significant higher morbidity and mortality after coronary intervention. Recently it was shown, that patients undergoing percutaneous coronary intervention for acute myocardial infarction have a significant higher risk of developing CIN. NonST-elevating myocardial infarction (NSTEMI) patients (pts) might be at an even higher risk developing CIN than patients with ST-elevating myocardial infarction (STEMI), because of presenting older and more often with diabetes. Methods In 392 consecutive ACS patients developing myocardial infarction and therefore undergoing emergent coronary angiography between October 2004 and March
Department of Cardiology and Pneumology, St. Marien Hospital Lu¨nen, Academic Teaching Hospital of the University of Mu¨nster, Lu¨nen, Germany Department of Cardiology and Angiology, Ruhr University of Bochum, Bochum, Germany Department of Nephrology, University of Du¨sseldorf, Du¨sseldorf, Germany Department of Cardiology, Pneumology, Nephrology and Intensive Care Medicine, Klinikum Lu¨nen, St. Marien Hospital Lu¨nen, Altstadtstr. 23, Lu¨nen 44534, Germany e-mail: wickenbrock.ingo@smh-online.de we measured serum creatinine concentration (Cr) at baseline and each day of the following 3 days. Contrast medium induced nephropathy was defined as an increase in Cr [ 0.5 mg/dl. ACS was defined according to the guidelines of the German Society of Cardiology. Results Overall, 392 pts were included: 203 (51.8%) with STEMI and 189 (48.2%) with NSTEMI. Patients with STEMI developed more often a cardiogenic shock (18 vs. 6%; P \ 0.001) whereas patients with NSTEMI were older (67 vs. 61 years; P \ 0.001) and presenting with a higher co-morbidity. Forty-five (11.5%) pts developed CIN; 22 (10.8%) in the STEMI group and 23(12.2%) in the NSTEMI group (P = 0.75). Patients developing CIN presented a more complicated clinical course and a significantly longer hospital stay (14 vs. 10 days; P \ 0.001). The mortality rate was also significantly higher (16 vs. 6%; P \0.05). Conclusion This prospective study showed no differences in the incidence of developing CIN in patients undergoing PCI for STEMI or NSTEMI, but the predisposing factors, however, differed significantly. Although STEMI patients needed significantly more contrast medium for revascularisation, they did not develop CIN more often. CIN was associated with higher in-hospital complication rate and mortality. Thus, better preventive strategies according to the different predisposing factors leading to CIN are needed to reduce morbidity and mortality, especially in high risk patients.

0 件のコメント:

コメントを投稿